Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Blood (2024) 144 (Supplement 1): 310.

https://doi.org/10.1182/blood-2024-193946

Published: 2024

Journal Articles

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Blood (2022) 140 (Supplement 1): 8845–8847.

https://doi.org/10.1182/blood-2022-165954

Published: 2022

Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Blood (2022) 140 (Supplement 1): 8976–8978.

https://doi.org/10.1182/blood-2022-163056

Published: 2022

Journal Articles

Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2021) 138 (Supplement 1): 2383.

https://doi.org/10.1182/blood-2021-145058

Published: 2021

Journal Articles

A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A -Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network

Inge M. Van Der Sluis, Paola De Lorenzo, Rishi Sury Kotecha, Andishe Attarbaschi, Gabriele Escherich, Karsten Nysom, Jan Stary, Alina Ferster, Benoit Brethon, Phillip Ancliff, Andrea Biondi, Maria Grazia Valsecchi, Rob Pieters

Blood (2021) 138 (Supplement 1): 361.

https://doi.org/10.1182/blood-2021-144843

Published: 2021

Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blood (2021) 137 (12): 1582–1590.

https://doi.org/10.1182/blood.2020007848

Published: 2021

Includes: Supplemental data

Journal Articles

Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD PhD, Gerhard Zugmaier, Noemi Mergen, MD, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rössig, William Kormany, MD, Puneeth Viswagnachar, Christiane Chen-Santel

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141336

Published: 2020

Journal Articles

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134303

Published: 2020

Journal Articles

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD, Gerhard Zugmaier, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rossig, Christiane Chen-Santel

Blood (2019) 134 (Supplement_1): 1294.

https://doi.org/10.1182/blood-2019-121615

Published: 2019

Journal Articles

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Emilie Saucier, Florence Rabian, MD, Hélène Boutroux, MD, Marion Strullu, MD, Karine Morand, MD, Florian Chevillon, MD, Benoit Brethon, MD, Nicolas Boissel, MD PhD, Guy Leverger, MD, André Baruchel, MD

Blood (2019) 134 (Supplement_1): 5130.

https://doi.org/10.1182/blood-2019-131062

Published: 2019

Journal Articles

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Blood (2019) 134 (Supplement_1): 2629.

https://doi.org/10.1182/blood-2019-122411

Published: 2019

Journal Articles

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Blood (2018) 132 (Supplement 1): 655.

https://doi.org/10.1182/blood-2018-99-112854

Published: 2018

Journal Articles

Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Charlotte Calvo, Benoit Brethon, Aurelie Cabannes-Hamy, MD, Dalila Adjaoud, MD, Benedicte Bruno, MD, Laurence Blanc, MD, Nicolas Boissel, MD PhD, Marie-Dominique Tabone, MD, Andre Baruchel, MD

Blood (2018) 132 (Supplement 1): 5203.

https://doi.org/10.1182/blood-2018-99-116360

Published: 2018

Journal Articles

High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

Franco Locatelli, Gerhard Zugmaier, Peter Bader, MD PhD, Sima Jeha, MD, Paul-Gerhardt Schlegel, MD, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD PhD, Benoit Brethon, Claudia Rossig, MD, Christiane Chen-Santel, MD

Blood (2018) 132 (Supplement 1): 1375.

https://doi.org/10.1182/blood-2018-99-109855

Published: 2018

Journal Articles

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

Arnaud Petit, Amélie Trinquand, Sylvie Chevret, Paola Ballerini, Jean-Michel Cayuela, Nathalie Grardel, Aurore Touzart, Benoit Brethon, Hélène Lapillonne, Claudine Schmitt, Sandrine Thouvenin, Gerard Michel, Claude Preudhomme, Jean Soulier, Judith Landman-Parker, Guy Leverger, Elizabeth Macintyre, André Baruchel, Vahid Asnafi

Blood (2018) 131 (3): 289–300.

https://doi.org/10.1182/blood-2017-04-778829

Published: 2018

Includes: Supplemental data

Journal Articles

Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines

Arnaud Petit, MD PhD, Amélie Trinquand, MD, Sylvie Chevret, MD PhD, Paola Fabiola Ballerini, MD PhD, Jean-Michel Cayuela, MD, Nathalie Grardel, MD, Aurore Touzart, MD, Benoit Brethon, MD, Hélène Lapillonne, MD PhD, Pascal Chastagner, MD, Claire Berger, MD, Gerard Michel, MD, Claude Preudhomme, MD PhD, Jean Soulier, MD PhD, Judith Landman-Parker, MD, Guy Leverger, MD, Elizabeth Macintyre, MD PhD, Andre Baruchel, MD PhD, Vahid Asnafi, MD PhD

Blood (2016) 128 (22): 1083.

https://doi.org/10.1182/blood.V128.22.1083.1083

Published: 2016

Journal Articles

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

Anne-Flore Derache, MD, Fanny Rialland, MD, Gerard Michel, MD, Yves Perel, MD, Virginie Gandemer, MD PhD, Pascale Blouin, MD, Odile Minckes, MD, Arnaud Petit, MD PhD, Andre Baruchel, MD PhD, Benoit Brethon, MD

Blood (2016) 128 (22): 5190.

https://doi.org/10.1182/blood.V128.22.5190.5190

Published: 2016

Journal Articles

Late Effects in Survivors of Infantile Acute Leukemia Are Less Severe Than Expected: A Study of the L.E.a Program

Blood (2016) 128 (22): 3571.

https://doi.org/10.1182/blood.V128.22.3571.3571

Published: 2016

Journal Articles

Immunophenotypic Profiling of Childhood B-Cell Precursor Acute Lymphoblastic Helps Identifying Genetic Subtypes, Including Recently Identified Ones

Elodie Lainey, PharmD/PhD, Aurelie Caye-Eude, PharmD, Lucile Broseus, Emmanuelle Clappier, PharmD, PhD, Wendy Cuccuini, MD PhD, Cristina Leschi, PharmD, Odile Fenneteau, PharmD, Jimmy Mullaert, Amandine Chaye, Ahlene Emam, Benoit Brethon, MD, Thierry Leblanc, MD, Andre Baruchel, MD, Helene Cave, PharmD, PhD

Blood (2016) 128 (22): 2910.

https://doi.org/10.1182/blood.V128.22.2910.2910

Published: 2016

Journal Articles

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

C. Michel Zwaan, MD PhD, Stefan Söderhäll, MD PhD, Benoit Brethon, MD, Matteo Luciani, MD, Carmelo Rizzari, MD, David Sternberg, MD PhD, Emmanuelle Besse, Catherine Dutreix, MD, Franca Fagioli, MD, Phoenix Ho, MD, Carlo Dufour, MD, Rob Pieters, MD PhD

Blood (2015) 126 (23): 2564.

https://doi.org/10.1182/blood.V126.23.2564.2564

Published: 2015

NARROW

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A -Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

Late Effects in Survivors of Infantile Acute Leukemia Are Less Severe Than Expected: A Study of the L.E.a Program

Immunophenotypic Profiling of Childhood B-Cell Precursor Acute Lymphoblastic Helps Identifying Genetic Subtypes, Including Recently Identified Ones

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only